ranolazine
Cardiovascular system (C01)US regulatory status: approved. Molecular target: Sodium channel protein type 4 subunit alpha.
- Target
- Sodium channel protein type 4 subunit alpha
- Mechanism
- Sodium channel protein type IV alpha subunit blocker
pharma · Cystic Fibrosis (CF) · Accidental Hypothermia · SION
Sionna Therapeutics
Sionna Therapeutics drug portfolio — 4 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Boston, USA HQ
2019 Founded
74 Employees
Public company Type
SION · NYSE Ticker
Company details
- Status
- Public
- HQ
- Boston, USA
- Founded
- 2019
- Employees
- 74
- Programs
- 5
- Drugs
- 4
- Patents
- 0
Sionna Therapeutics pipeline
Portfolio lens on 4 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Sionna Therapeutics drug portfolio — 4 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
US regulatory status: approved. Mechanism: Diagnostic agent.
- Mechanism
- Diagnostic agent
-
Development asset linked to Sionna Therapeutics in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Plasminogen.
- Target
- Plasminogen
- Mechanism
- Plasminogen inhibitor